Search

everythinglearnresearchcommunity

for

Search:↓

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.